Sign in Subscribe

Archive

A collection of 715 issues

Latest

Alpelisib plus capecitabine shows modest activity in PIK3CA-mutant metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Alpelisib plus capecitabine shows modest activity in PIK3CA-mutant metastatic colorectal cancer — Scientific Reports A phase 2 study tested alpelisib (a PI3K inhibitor) combined with capecitabine in 26 patients with PIK3CA-mutant metastatic colorectal cancer who had progressed after standard chemotherapy. The trial was

Re-challenging BRAF V600E tumors with encorafenib, cetuximab, and nivolumab shows success

Skip to content The CRC Digest ▸ TREATMENT Re-challenging BRAF V600E tumors with encorafenib, cetuximab, and nivolumab shows success — Clinical Colorectal Cancer A case report from the AGMT mCRC Registry documented successful re-challenge with encorafenib and cetuximab combined with nivolumab in a patient with BRAF V600E mutated, mismatch-repair-proficient (pMMR) metastatic colorectal

Blood test detects colorectal cancer recurrence earlier than imaging in stage III patients

Skip to content The CRC Digest ▪ SCREENING Blood test detects colorectal cancer recurrence earlier than imaging in stage III patients — Cancer Diagnosis & Prognosis A retrospective case series of four patients with stage III colorectal cancer demonstrated the clinical utility of the Signatera assay, a personalized circulating tumor DNA (ctDNA)

Adding celecoxib to immunotherapy increases complete response in MSI-H colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Adding celecoxib to immunotherapy increases complete response in MSI-H colorectal cancer — Lancet Oncology A phase 2 trial tested whether adding celecoxib (a COX-2 inhibitor) to the immunotherapy drug toripalimab would improve outcomes in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H)

CRC Research Update — July 03, 2026

Today's colorectal cancer research highlights

New FAK inhibitor shows promise in KRAS-mutant colorectal cancer

Skip to content The CRC Digest New FAK inhibitor shows promise in KRAS-mutant colorectal cancer Researchers designed a focal adhesion kinase (FAK) inhibitor (compound 7g) that demonstrated antiproliferative activity in KRAS-mutant HCT116 colorectal cancer cells and showed 66.5% tumor growth inhibition in mouse models. (Bioorg Chem) This content is

CRC Research Finding

Skip to content The CRC Digest ◇ Mismatch repair-deficient CRC with bowel obstruction shows excellent response to immunotherapy A case series reports that patients with mismatch repair-deficient (dMMR) colorectal cancer presenting with bowel obstruction achieved excellent responses to immunotherapy. (Annals of Coloproctology) This content is informational only and does not constitute

CRC Research Update — July 02, 2026

Today's colorectal cancer research highlights

KRAS Mutations Predict Worse Outcomes After Liver Metastasis Surgery

Skip to content The CRC Digest KRAS Mutations Predict Worse Outcomes After Liver Metastasis Surgery In 190 patients who had curative liver surgery for colorectal metastases, KRAS mutations (37.9% of patients) were associated with significantly worse overall and recurrence-free survival and more aggressive recurrence patterns. (Surgery Today) This content

Early-Onset CRC Rising Across Europe with Regional Disparities

Skip to content The CRC Digest Early-Onset CRC Rising Across Europe with Regional Disparities Incidence of colorectal cancer in people under 50 is rising across Europe, with stark regional differences in incidence and mortality; early-onset disease shows a predominance for distal tumors and aggressive features. (European Journal of Cancer) This